449 related articles for article (PubMed ID: 31210292)
1. MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.
Zhang L; Liu XL; Yuan Z; Cui J; Zhang H
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4663-4672. PubMed ID: 31210292
[TBL] [Abstract][Full Text] [Related]
2. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
Dai C; Xie Y; Zhuang X; Yuan Z
Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-23b suppresses cervical cancer biological progression by directly targeting six1 and affecting epithelial-to-mesenchymal transition and AKT/mTOR signaling pathway.
Li YM; Li XJ; Yang HL; Zhang YB; Li JC
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4688-4697. PubMed ID: 31210295
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.
Cui L; Zhou H; Zhao H; Zhou Y; Xu R; Xu X; Zheng L; Xue Z; Xia W; Zhang B; Ding T; Cao Y; Tian Z; Shi Q; He X
BMC Cancer; 2012 Nov; 12():546. PubMed ID: 23173671
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-99a-5p alleviates atherosclerosis via regulating Homeobox A1.
Han Z; Guan Y; Liu B; Lin Y; Yan Y; Wang H; Wang H; Jing B
Life Sci; 2019 Sep; 232():116664. PubMed ID: 31325426
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-99a inhibits tumor aggressive phenotypes through regulating HOXA1 in breast cancer cells.
Wang X; Li Y; Qi W; Zhang N; Sun M; Huo Q; Cai C; Lv S; Yang Q
Oncotarget; 2015 Oct; 6(32):32737-47. PubMed ID: 26417931
[TBL] [Abstract][Full Text] [Related]
7. MiR-181d inhibits cell proliferation and metastasis through PI3K/AKT pathway in gastric cancer.
Jiang K; Xie LF; Xiao TZ; Qiu MY; Wang WL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8861-8869. PubMed ID: 31696473
[TBL] [Abstract][Full Text] [Related]
8. MiR-99a inhibits cell proliferation of nasopharyngeal carcinoma by targeting mTOR and serves as a prognostic factor.
Wu SH; Han L; Lu BC; Wang HY; Zheng CP
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2053-2061. PubMed ID: 30915749
[TBL] [Abstract][Full Text] [Related]
9. The lncRNA SNHG15/miR-18a-5p axis promotes cell proliferation in ovarian cancer through activating Akt/mTOR signaling pathway.
Zhang J; Wang L; Jiang J; Qiao Z
J Cell Biochem; 2020 Dec; 121(12):4699-4710. PubMed ID: 33135285
[TBL] [Abstract][Full Text] [Related]
10. MiR-99a suppresses cell migration and invasion by regulating IGF1R in gastric cancer.
Xu XL; Guo AX; Pan QY; Chang AL; Zhao CR
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7375-7382. PubMed ID: 31539124
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA FTX promotes epithelial-mesenchymal transition of epithelial ovarian cancer through modulating miR-7515/TPD52 and activating Met/Akt/mTOR.
Li Y; Zhu X; Zhang C; Yin Y; Chen L; Liu Y; He A; Xia F
Histol Histopathol; 2023 Dec; 38(12):1487-1498. PubMed ID: 37140169
[TBL] [Abstract][Full Text] [Related]
12. MiRNA-92a promotes cell proliferation and invasion through binding to KLF4 in glioma.
Liu PJ; Ye YX; Wang YX; Du JX; Pan YH; Fang XB
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6612-6620. PubMed ID: 31378903
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.
Liu X; Li G
Int J Clin Exp Pathol; 2015; 8(9):10605-14. PubMed ID: 26617770
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-125b Suppresses Ovarian Cancer Progression via Suppression of the Epithelial-Mesenchymal Transition Pathway by Targeting the SET Protein.
Ying X; Wei K; Lin Z; Cui Y; Ding J; Chen Y; Xu B
Cell Physiol Biochem; 2016; 39(2):501-10. PubMed ID: 27383536
[TBL] [Abstract][Full Text] [Related]
16. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
17. The miRNA mir-582-3p suppresses ovarian cancer progression by targeting AKT/MTOR signaling
Dai T; Liang J; Liu W; Zou Y; Niu F; Li M; Zhang H; Li C; Fan M; Cui G
Bioengineered; 2021 Dec; 12(2):10771-10781. PubMed ID: 34793263
[TBL] [Abstract][Full Text] [Related]
18. MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells.
Dong P; Xiong Y; Watari H; Hanley SJ; Konno Y; Ihira K; Yamada T; Kudo M; Yue J; Sakuragi N
J Exp Clin Cancer Res; 2016 Sep; 35(1):132. PubMed ID: 27596137
[TBL] [Abstract][Full Text] [Related]
19. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
Xu JH; Wang Y; Xu D
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
[TBL] [Abstract][Full Text] [Related]
20. Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10.
Fan L; Lei H; Zhang S; Peng Y; Fu C; Shu G; Yin G
Theranostics; 2020; 10(13):5895-5913. PubMed ID: 32483426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
